A phase II combination trial of lonafarnib and pegylated interferon lambda in hepatitis delta virus infected patients

Trial Profile

A phase II combination trial of lonafarnib and pegylated interferon lambda in hepatitis delta virus infected patients

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Lonafarnib (Primary) ; Peginterferon lambda-1a (Primary)
  • Indications Hepatitis D
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Sep 2016 New trial record
    • 10 Aug 2016 According to Eiger BioPharmaceuticals media release, this trial is likely to begin in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top